According to GlobalData’s medical device pipeline database, 15 Influenza Tests devices are in various stages of development globally. GlobalData’s report Influenza Tests provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, 13 are in active development, while the remaining two are in an inactive stage of development. There are nine products in the early stages of development, and the remaining four are in the late stages of development.
This segment includes Influenza Antigen Tests, Influenza Multiplex NAATs and Influenza Lowplex Nucleic Acid Amplification Tests (NAATs)
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Influenza Tests pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Influenza Tests devices. Overall, most of these Influenza Tests pipeline devices are being developed by private entities.
Key players involved in the active development of Influenza Tests include Guangzhou Wondfo Biotech, Kaligia Biosciences, Nanohmics, RNA Disease Diagnostics, Senzo, SpinChip Diagnostics, Techinvention Lifecare, Virax Biolabs Group, 3a-Diagnostics and Abionic.
For a complete picture of the developmental pipeline for Influenza Tests devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.